tiprankstipranks
Virax Biolabs Group Ltd. Class A (VRAX)
NASDAQ:VRAX
US Market
Holding VRAX?
Track your performance easily

Virax Biolabs Group Ltd. Class A (VRAX) Income Statement

33 Followers

Virax Biolabs Group Ltd. Class A Income Statement

Last quarter (Q ), Virax Biolabs Group Ltd. Class A's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Virax Biolabs Group Ltd. Class A's net income was $―. See Virax Biolabs Group Ltd. Class A’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Mar 23Mar 22Mar 21Mar 20
Total Revenue
-$ 8.56K-$ 123.82K$ 99.88K
Cost of Revenue
-$ 9.93K-$ 133.25K$ 54.13K
Gross Profit
-$ -1.36K-$ -9.43K$ 45.75K
Operating Expense
-$ 5.73M$ 1.73M$ 635.10K$ 696.99K
Operating Income
-$ -5.73M$ -1.73M$ -644.54K$ -651.24K
Net Non Operating Interest Income Expense
---$ -28.64K$ -90.69K
Other Income Expense
-$ 5.17M$ 3.38M$ 266.00$ 2.47K
Pretax Income
-$ -16.37M$ -5.21M$ -672.91K$ -739.46K
Tax Provision
---$ 0.00$ 0.00
Earnings From Equity Interest Net Of Tax
-$ -111.00---
Net Income Common Stockholders
-$ -16.37M$ -5.25M$ -650.98K$ -710.44K
Basic EPS
-$ -0.51$ -0.18$ -0.06$ -0.06
Diluted EPS
-$ -0.51$ -0.18$ -0.06$ -0.06
Basic Average Shares
-$ 10.63M$ 9.56M$ 11.37M$ 11.37M
Diluted Average Shares
-$ 10.63M$ 9.56M$ 11.37M$ 11.37M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
-$ 5.74M$ 1.73M$ 768.36K$ 751.12K
Net Income From Continuing And Discontinued Operation
-$ -16.37M$ -5.25M$ -650.98K$ -710.44K
Normalized Income
---$ -650.98K$ -710.44K
Interest Expense
---$ 28.64K$ 90.69K
EBIT
-$ -16.36M$ -5.19M$ -644.27K$ -648.77K
EBITDA
-$ -16.36M$ -5.19M$ -644.27K$ -648.77K
Currency in USD

Virax Biolabs Group Ltd. Class A Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis